Table 5.

Results of Questions 11–13 and comparison with the previous survey. In all comparisons p > 0.05.

Question 11		Current survey (n = 589)	Previous survey (n = 379)
If a biosimilar is prescribed and explained to you by your treating physician:	(a) You will be fully confident	205 (34.8%)	123 (32.4%)
	(b) You will be worried but you will accept the treatment	219 (37.2%)	146 (38.5%)
	(c) You will probably not accept it and express yourself on this matter	72 (12.2%)	48 (12.7%)
	(d) You will ask another physician	43 (7.3%)	23 (6.1%)
	(e) You don’t know	50 (8.5%)	39 (10.3%)
Question 12		Current survey (n = 587)	Previous survey (n = 376)
If the pharmacist hands out the biosimilar, changing the initial prescription without the consent of the prescribing physician:	(a) You will accept it because of the lower cost of the biosimilar	21 (3.6%)	13 (3.5%)
	(b) You will accept it because of available scientific evidence	64 (10.9%)	72 (19.2%)
	(c) You disagree, but you acknowledge that you will have to accept it	111 (18.9%)	52 (13.8%)
	(d) You will try to obtain the reference drug	391 (66.6%)	239 (63.6%)
Question 13		Current survey (n = 586)	Previous survey (n = 379)
After starting a treatment with biosimilar:	(a) You will carefully follow the treatment	330 (56.3%)	200 (52.7%)
	(b) You will be worried and will probably stop the treatment at the first doubt or adverse event	111 (18.9%)	75 (19.8%)
	(c) You will be worried, but the fact that the treatment has been approved by the European Medicines Agency is reassuring	145 (24.7%)	104 (27.4%)